leadf
logo-loader
viewAcasti Pharma Inc

Acasti Pharma names Brian D. Ford as new finance chief as it explores "strategic options and opportunities"

"Brian brings strong leadership skills, as well as analytical and financial skills that we believe will add significant value," said CEO Jan D'Alvise

Acasti Pharma Inc -
Ford has been responsible for developing business recovery strategies, negotiating M&A transactions, as well as managing quarterly and yearly accounting reports

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) told investors it has hired seasoned executive in the healthcare and financial sectors Brian D. Ford as its chief financial officer, effective September 14 this year.

"Brian brings strong leadership skills, as well as analytical and financial skills that we believe will add significant value. As we explore strategic options and opportunities, we believe Brian’s experience in problem solving, strategic transactions, and M&A will prove beneficial," said Jan D’Alvise, CEO of biopharma firm Acasti in a statement.

READ: Acasti Pharma reports results from Phase 3 TRILOGY 2 study of lead drug CaPre

"Brian will assume all responsibilities formerly held by Jean-Francois Boily, who recently resigned, as previously announced. We thank Mr. Boily for his contributions to Acasti and wish him well on his future endeavours."

With over 30 years' experience, Ford has been responsible for developing business recovery strategies, negotiating M&A transactions, as well as managing quarterly and yearly accounting reports, said Acasti.

Most recently, he was chief financial officer and senior business advisor at a private group of Ontario based medical clinics, including the largest chronic pain management practice in Canada.

During his position as CFO and Senior Business Advisor, Ford significantly improved the company's performance and was instrumental in preparing the firm for initial public offering (IPO).

Prior to that, Ford served as CFO at Telesta Therapeutics, where he developed a new business plan.

"I believe my experience in evaluating strategic opportunities as well as M&A transactions will provide valuable insights for Acasti as we evaluate our options moving forward," said Ford.

Contact the author at giles@proactiveinvestors.com

Quick facts: Acasti Pharma Inc

Price: 0.285 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $27.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 11/26/2019

2 min read